In conclusion, rh‐endostatin plus platinum‐based chemotherapy significantly improved the PFS, OS, and DCR in advanced non‐driver gene mutation NSCLC patients with well tolerance. Here, COL18A1 is linked to non-small cell lung carcinoma.